Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Stem Cell Res. 2010 Aug 6;5(3):212–225. doi: 10.1016/j.scr.2010.07.003

Figure 3. CD45+CD19− xenograft tumors recapitulate heterogeneity of patient samples.

Figure 3

Figure 3

(A); FACS analysis of cell surface antigens in CD45+CD19− xenograft tumors, as compared to patient tumor cells. Only cells expressing human CD45 were analyzed. Xenograft tumors generated from patients 1 and 4 are shown, although similar results were obtained from all xenograft tumors injected with other patient samples.

(B); t(11:14)(q13:q32) translocations were detected in patient tumor cells (Pt1) as well as CD45+CD19− xenograft tumors as determined by FISH. Note the yellow fusion signals (arrows). Boxed regions in left panels are shown at higher magnification in right panels.